Please ensure Javascript is enabled for purposes of website accessibility

Aimmune's Launch of Peanut Allergy Drug Will Take Time

By Jim Crumly – Feb 28, 2020 at 7:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A month after the drug's approval, Aimmune is still working on getting it to patients.

Aimmune Therapeutics (AIMT), a biopharmaceutical company that specializes in treatments for life-threatening food allergies, reported  fourth-quarter results Thursday after the market close. Despite being down 14% at one point in Friday's trading, shares closed down only 2.5% on a day the market took a beating.

Investors weren't interested as much in the financials as they were to hear about the launch of Aimmune's peanut allergy drug, Palforzia, which was approved by the U.S. Food and Drug Administration (FDA) on Jan. 31. The company didn't take in any revenue in the quarter ended Dec. 31, as expected. The Palforzia launch is progressing, but complexities relating to the management of risk to patients means that revenue will ramp up slowly during the year.

Girl holding up hand to a bowl of peanuts.

Image source: Getty Images.

Palforzia is a complex biologic drug derived from peanuts that works by desensitizing the patient to the allergen and has been approved for children aged 4 through 17. Since there is a risk that patients could have a dangerous allergic reaction to the medicine itself, the FDA specified a Risk Evaluation and Mitigation Strategy (REMS) that must be followed in order to make the medicine available. Patients and prescribing physicians must be enrolled in the program, the initial doses need to be administered in healthcare settings where the patient can be monitored, and those clinics and the dispensing pharmacies need to be certified.

Aimmune set up a website for certification and enrollment, and 300 physicians had enrolled after four days, which was a good start. Yet the complicated process will take time with competition on the horizon, and the company still has work to do to get the drug covered by payer formularies.

Looking ahead, the company expects a decision on the drug by the European Medicines Agency in Q4 and the completion of a phase 3 trial of Palforzia in children under 4 years old in the second half of the year.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aimmune Therapeutics, Inc. Stock Quote
Aimmune Therapeutics, Inc.
AIMT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.